Stocktoria
Aldeyra Therapeutics, Inc. ALDX
Aldeyra Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M | $24.7M | $44.4M | $29.8M | $16.3M | $13.2M |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M | -$36.4M | -$63.1M | -$39.7M | -$22.5M | -$18.7M |
| Interest expense | — | — | $2.1M | $1.7M | $1.7M | $1.9M | $603,846 | $146,792 | $113,453 | $105,509 |
| Income tax | $0 | $1,000 | $0 | $0 | $0 | -$479,265 | -$1.3M | $0 | $0 | $0 |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M | -$37.6M | -$60.8M | -$38.9M | -$22.3M | -$18.7M |
| EPS (diluted) | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 | — | — | — | — | — |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M | -$37.5M | -$45.0M | -$29.9M | -$19.2M | -$15.1M |
| Free cash flow | — | — | -$30.3M | -$56.7M | -$42.6M | — | -$45.0M | -$30.1M | -$19.2M | -$15.2M |
| Cash & equivalents | $70.0M | $54.5M | — | $144.4M | $229.8M | $77.9M | $44.4M | $47.4M | $20.0M | $12.0M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M | $83.4M | $75.5M | $95.1M | $44.2M | $25.2M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M | $23.8M | $27.4M | $8.5M | $4.6M | $3.5M |
| Shareholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M | $59.5M | $48.1M | $86.6M | $39.6M | $21.6M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.